Antifungal prophylaxis in HIV-seropositive liver transplant recipients

被引：1

作者：

Pozo Laderas, Juan Carlos ^{[1
,2
]}

机构：

[1] Hosp Univ Reina Sofia, Serv Med Intens, Cordoba, Spain

[2] Inst Maimonides Invest Biomed Cordoba IMIBIC, Cordoba, Spain

来源：

REVISTA IBEROAMERICANA DE MICOLOGIA | 2011年 / 28卷 / 04期

关键词：

Liver transplantation; HIV seropositive; Antifungal prophylaxis; SOLID-ORGAN TRANSPLANTATION; INVASIVE FUNGAL-INFECTIONS; PLACEBO-CONTROLLED TRIAL; AMPHOTERICIN-B; MANAGEMENT; FLUCONAZOLE; CANDIDIASIS; OUTCOMES; METAANALYSIS; MULTICENTER;

D O I：

10.1016/j.riam.2011.03.002

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Background: Seropositive human immunodeficiency virus (HIV) patients have a high prevalence of chronic liver disease for which liver transplantation is the only possible treatment. Risk of fungal infection in this population may be very high. Case report: We describe the clinical course of the early postoperative period in a patient coinfected with HIV and hepatitis C virus undergoing liver transplantation. We discuss antifungal prophylaxis indications and drugs of choice in relation to their efficacy and safety profile. Other medical treatments are described, as well as possible pharmacokinetic interactions. Conclusions: Antifungal prophylaxis with anidulafungin has proven effective and has presented no significant adverse effects on a patient at high risk of fungal infection and multiple risk factors for drug interactions. (C) 2011 Revista Iberoamericana de Micologia. Published by Elsevier Espana, S.L. All rights reserved.

引用

页码：183 / 190

页数：8

共 35 条

[1] Aguado Jose M, 2008, Enferm Infecc Microbiol Clin, V26 Suppl 14, P29
[2] [Anonymous], COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004291.PUB2
[3] Infectious disease assessment in solid organ transplant candidates
Ayats-Ardite, J
Cisneros-Herreros, JM
Pérez-Sáenz, JL
de la Torre-Cisneros, J
[J]. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2002, 20 (09): : 448 - 461
[4] CANAS E, 2000, 13 INT AIDS C DURB
[5] CASTON JJ, 2003, INFECCION VIH GUIA P, P497
[6] Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?
Charlier, C
Hart, E
Lefort, A
Ribaud, P
Dromer, F
Denning, DW
Lortholary, O
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (03) : 384 - 410
[7] Mechanisms of clinically relevant drug interactions associated with tacrolimus
Christians, U
Jacobsen, W
Benet, LZ
Lampen, A
[J]. CLINICAL PHARMACOKINETICS, 2002, 41 (11) : 813 - 851
[8] Antifungal prophylaxis in liver transplant patients: A systematic review and meta-analysis
Cruciani, Mario
Mengoli, Carlo
Malena, Marina
Bosco, Oliviero
Serpelloni, Giovanni
Grossi, Paolo
[J]. LIVER TRANSPLANTATION, 2006, 12 (05) : 850 - 858
[9] CLINICAL PHARMACOKINETICS OF FLUCONAZOLE
DEBRUYNE, D
RYCKELYNCK, JP
[J]. CLINICAL PHARMACOKINETICS, 1993, 24 (01) : 10 - 27
[10] Echinocandin antifungal drugs
Denning, DW
[J]. LANCET, 2003, 362 (9390) : 1142 - 1151

← 1 2 3 4 →